3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Malignant Solid Tumors
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Thiotepa
3
Cyclophosphamide
3
sargramostim
2
Topotecan
2
Melphalan
2
Ifosfamide
2
Etoposide
2
Carboplatin
2
Busulfan
2
racotumomab
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
entinostat
1
cixutumumab
1
atezolizumab
1
alvocidib
1
Thrombopoietin
1
Thalidomide
1
Stem Cell Transplantation
1
Sirolimus
1
Simvastatin
1
Radiotherapy, Intensity-Modulated
1
Platinum
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Mesna
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Wilms Tumor
×
pegylated granulocyte colony-stimulating factor
×
Other solid neoplasm
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled